COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company’s board of directors (the “Board”), has been appointed Interim Chief Executive Officer, effective immediately.

Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer.

“As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition leadership,” said Robert Seager, Chair of the Human Resources, Nominating and Governance Committee.

“Peter is already deeply involved in driving the strategic reorientation of the Company and has a proven track record of creating value with similarly situated businesses. We are confident that the Company will be well-served by Peter’s leadership at this critical juncture.”

Mr. Puccetti said, “In my expanded role as Chairman and Interim CEO, I plan on continuing to strengthen operational performance, while working to create the conditions necessary for driving shareholder value.”

He added, “On behalf of everyone at COSCIENS, I want to thank Anna for her professionalism, leadership, and contributions. We wish her all the best in her future endeavors.”

### About COSCIENS Biopharma Inc.

COSCIENS is a life science company with a diverse portfolio focused on the development of natural, plant-based active ingredients and engaged in the commercialization of pharmaceutical and diagnostic products.

COSCIENS’ natural active ingredient business leverages the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide.

COSCIENS’ lead pharmaceutical product Macimorelin (Macrilen; Ghryvelin) is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) under the symbol “CSCI.” The Company’s common shares were assigned the trading symbol “CSCIF” by FINRA’s Department of Market Operations for quoting and trading in the market for unlisted securities (i.e., the “over-the-counter market” or “OTC” market) in the United States as of September 4, 2025.

For more information, please visit COSCIENS’ website at [www.cosciensbio.com](http://www.cosciensbio.com).

### Forward-Looking Statements

Certain statements in this news release, referred to herein as “forward-looking statements,” constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” under the provisions of Canadian securities laws.

All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements.

When used in this release, words such as “anticipate,” “assume,” “believe,” “could,” “expect,” “forecast,” “future,” “goal,” “guidance,” “intend,” “likely,” “may,” “would,” or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are generally intended to identify forward-looking statements, although not all forward-looking statements include such words.

Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations of the Interim Chief Executive Officer. These statements are based on current expectations and assumptions, including factors or assumptions applied in drawing conclusions or making forecasts or projections, based on historical trends, current conditions, and expected future developments.

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties.

The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in “Risks Relating to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024.

Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates.

The Company disclaims any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events, or developments, unless required to do so by a governmental authority or applicable law.

### Issuer Contact:

**Peter H. Puccetti**
Interim CEO and Chairman of the Board
pp@cosciensbio.com

**Giuliano La Fratta**
Chief Financial Officer
glafratta@cosciensbio.com

### Investor Contact:

IR@cosciensbio.com
https://www.globenewswire.com/news-release/2025/11/14/3188655/0/en/COSCIENS-Biopharma-Inc-Announces-Leadership-Change.html

Ripple and Mastercard Test Secret Stablecoin System for Card Payments

**Ripple and Mastercard Partner to Test RLUSD Stablecoin Payments for Real-Time Fiat Card Settlements**

Ripple has announced a new partnership with Mastercard, WebBank, and Gemini to test RLUSD stablecoin payments. This collaboration aims to leverage Ripple’s XRPL platform to process real-time fiat card settlements securely and efficiently. The trial will evaluate the potential of blockchain technology to support mainstream financial transactions.

### Ripple Partners with Mastercard for On-Chain Settlements

In this collaboration, Ripple will work with Mastercard and WebBank to enable on-chain settlements for fiat card payments. The test will assess how the RLUSD stablecoin performs within Mastercard’s extensive global payment network. Additionally, the trial will examine compliance and operational stability for regulated financial institutions involved.

Mastercard plans to integrate Ripple’s XRPL platform to manage the settlement layer of these payments, aiming to bridge blockchain efficiency with traditional financial systems. The companies expect this system to provide fast, transparent settlements to participating institutions.

Sherri Haymond, Global Head of Digital Commercialization at Mastercard, commented on the partnership’s goal:
“Through our partnerships with Ripple, Gemini, and WebBank, we’re using our global payments network to bring regulated, open-loop stablecoin payments into the financial mainstream.” She emphasized Mastercard’s belief that stablecoins can offer a secure and compliant transaction layer for banks and issuers.

### RLUSD Stablecoin Enters Regulated Payment Testing

Central to this pilot program is Ripple’s RLUSD stablecoin. The coin will facilitate settlements between Mastercard and WebBank, the issuer of the Gemini credit card involved in the trial. This initiative marks the first use of a regulated on-chain stablecoin for fiat settlement.

Currently, the RLUSD token has a total supply of $2 billion, with steady growth in the stablecoin market. Ripple envisions RLUSD as a reliable digital asset capable of supporting large-scale institutional transactions. The company highlights RLUSD’s controlled expansion as a reflection of its commitment to compliance and long-term stability.

Jason Lloyd, President and CEO of WebBank, emphasized the bank’s role in the project:
“Banks are uniquely positioned to bridge innovative blockchain technology with the stability of the traditional financial system.” WebBank will oversee settlement functions, ensuring regulatory oversight throughout the testing phase.

### XRPL to Demonstrate Institutional Settlement Capacity

The XRPL platform will power all transactions within this trial. Ripple originally developed XRPL to handle up to 1,500 transactions per second with minimal costs. Now, the system will be evaluated for its capacity to deliver institutional-grade payment efficiency.

Ripple President Monica Long stated that regulated stablecoins like RLUSD have the potential to enhance financial settlement systems. She added that Ripple’s goal is to expand XRPL’s presence in institutional finance through compliance-driven innovation and plans to integrate future programs once regulatory approvals are secured.

Currently, the XRPL network supports about 7,000 active wallets daily. Ripple continues to maintain XRP as one of the top 10 cryptocurrency assets by market value, with XRP trading steadily at around $2.31, reflecting consistent market interest.

### Regulatory Approval and Future Outlook

Before full deployment, regulators must approve RLUSD’s onboarding. Ripple and its partners will coordinate settlement processes once the necessary approvals are granted. This trial represents a landmark collaboration between a regulated U.S. bank and an on-chain settlement network.

This partnership signals a significant step toward integrating blockchain technology with traditional financial infrastructures, aiming to provide faster, more transparent, and compliant payment solutions.

*Source: Blockonomi*
https://bitcoinethereumnews.com/tech/ripple-and-mastercard-test-secret-stablecoin-system-for-card-payments/

Inside Japan’s Great Transformation: Mazda’s Five-Year Reform Plan

Inside its training center in Hiroshima, employees of all ages and departments—many meeting for the first time—are engaged in workshops exploring the company’s corporate culture, known as “food,” and what it should represent. Participants first reflect individually, then discuss in pairs, and finally present their ideas to the group—a process repeated across various themes.

The cultural reform initiative, launched in November 2023, is a cornerstone of Mazda’s five-year transformation plan. In May, the company rented a local soccer stadium to train 4,000 employees, and nearly all staff have now completed the program.

The project unfolds in three phases: first, defining the desired culture through training; second, embedding it in everyday workplace behavior; and third, establishing it as a daily habit. Mazda sees this internal evolution as essential for survival as electrification, environmental concerns, and other sweeping changes reshape the industry.

“We’re not a large company by scale,” one executive noted, “so human creativity, imagination, and uniqueness are critical to generating new value. We must cultivate our organizational culture anew.”

The company’s journey is not without resistance. Some employees question whether management fully supports the changes, while others see altering executive mindsets as key to success. Yet the resolve remains strong as Mazda pushes toward a future where a new corporate culture becomes its competitive edge.

Beyond corporate reinvention, Japan is also witnessing groundbreaking research aimed at addressing the climate crisis. On August 5th, temperatures in Gunma Prefecture hit a record 41.8°C—the highest ever recorded in Japan—with the Meteorological Agency warning that above-average heat could persist through November.

As the world works to reduce CO2 emissions from vehicles and fossil fuels, a pioneering project in Tanegashima, Kagoshima Prefecture, is exploring a domestic biofuel alternative derived from sugarcane. At the center of the effort is Satoshi Obara, a special professor at the University of Tokyo, who has spent two decades developing new sugarcane varieties in collaboration with the Kyushu Okinawa Agricultural Research Center.

One such variety, named Haru no Ougi, yields 30–50% more than conventional strains and withstands the island’s frequent typhoons without bending, making it ideal for mechanical harvesting.

Obara, who once worked on biofuel commercialization in the private sector, left his company to pursue this vision independently. His goal: to create a renewable, domestically produced fuel without relying on imported oil or external electricity—a bold attempt to build a sustainable energy future from Japan’s farmland.

Meanwhile, in the resort sector, Spa Resort Hawaiians—a tropical-themed leisure facility in Iwaki, Fukushima Prefecture, known for its towering 40-meter waterslide and daily Hula Girl dance shows—is fighting for survival.

Operated by local company Joban Kosan and celebrating its 60th anniversary next year, Hawaiians has faced severe financial challenges. The 2011 Great East Japan Earthquake forced a six-month closure, while the COVID-19 pandemic caused an additional three-month shutdown, leaving the company with about 28 billion yen in debt and aging facilities.

In November 2023, U.S. investment fund Fortress Investment Group, which manages over 7 trillion yen in assets and previously acquired Seibu Holdings, launched a takeover bid, acquiring more than 85% of Joban Kosan’s shares.

“Given the current financial state, it would be difficult for Hawaiians to remain competitive over the next 50 or 60 years without major change,” said Shunsuke Yamamoto, who led the acquisition.

Fortress plans a sweeping overhaul of the resort, investing heavily to modernize facilities and align them with the expectations of Japanese travelers who have experienced Hawaii firsthand.

Hawaiians’ transformation is part of a broader trend of foreign investment reshaping Japan’s hospitality landscape. Large-scale resorts from the bubble era are being rebuilt from the ground up, reflecting a strategic push to redefine domestic travel experiences.

But not all of Japan’s battles involve boardrooms or laboratories—some are fought in the fields. In Tochigi Prefecture, wild boars, once rare, have proliferated in recent years, wreaking havoc on agriculture. They destroy sweet potato fields, trample rice paddies, and even roll in fields to remove parasites, knocking over crops and reducing grain quality.

Damages nationwide from wild animal incursions now total 16.4 billion yen annually. Despite these losses, Japan’s hunter population has fallen to less than half its previous size, with about 60% now over 60 years old. Local governments are struggling to respond.

Veteran hunter Kiyoshi Sekiguchi, 75, who captured 30 boars last year, says manpower is the biggest obstacle: “There’s nobody left to set traps or check them.” Municipalities offer 16,000 yen per animal, but the shortage of younger hunters—many of whom cannot leave their jobs for extended periods—remains a critical challenge.

The consequences go beyond crops. Wild animals cause traffic accidents, spread disease, and pose risks to human safety.

Yet new business models are emerging to tackle the crisis. In Chiba Prefecture, companies are making it easier for people to enter the hunting industry, including offering training for trap licenses. In Hokkaido, female entrepreneurs are launching ventures that connect hunters with consumers seeking game meat, creating a market-driven incentive for wildlife control.
https://newsonjapan.com/article/147245.php